6533b82ffe1ef96bd1295b83

RESEARCH PRODUCT

Bone marrow fibrosis and diagnosis of essential thrombocythemia

Ayalew TefferiMartin GriesshammerJames W. VardimanGunnar BirgegårdVito FrancoHans Michael KvasnickaJuergen ThieleHeinz GisslingerAttilio Orazi

subject

Cancer Researchmedicine.medical_specialtyPathologyessential thrombocythemiabusiness.industryEssential thrombocythemiaMEDLINEBone marrow fibrosismedicine.diseasemyeloproliferative neoplasmsOncologyInternal medicineCohortMedicinePatient databasebusinessBone marrow fibrosi

description

However, there are serious issues to beraisedconcerningtheauthors’analysisoftheclinicaldata,thecriteriausedtodiagnoseET,andthequantificationoffibrosis.Altogethertheauthors compared a heterogenous patient database, which included311 patients evaluated for presenting features, 299 for response totherapy,361forcomplicationrates,97forprogressionoffibrosis,andfour for reversal of BM fibrosis, so no single cohort with consistentfeatures was described throughout the study of 361 patients. Forexample, for the analysis of progression of fibrosis, only 97 (12%) oftheoriginal809patientsenteredintheUK-PT1trial

yearjournalcountryeditionlanguage
2009-12-01
10.1200/jco.2009.24.3485http://hdl.handle.net/10447/41548